Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MHC/HLA Class I Loss in Cancer Cells
Federico Garrido
Advances in experimental medicine and biology (2019), pp. 15-78
Closed Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Tumor-Infiltrating Natural Killer Cells
Beatriz Cózar, Marco Greppi, Sabrina Carpentier, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 34-44
Open Access | Times Cited: 344
Cancer Vaccines, Adjuvants, and Delivery Systems
Samantha Paston, Victoria A. Brentville, Peter Symonds, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 143
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini, Kerry Fisher, Leonard W. Seymour
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002899-e002899
Open Access | Times Cited: 137
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma
Giacomo Oliveira, Kari Stromhaug, Nicoletta Cieri, et al.
Nature (2022) Vol. 605, Iss. 7910, pp. 532-538
Open Access | Times Cited: 125
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Esther Schoutrop, Lidia Moyano‐Galceran, Stéphanie Lheureux, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 207-223
Open Access | Times Cited: 88
Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Maria Karasarides, Alexandria P. Cogdill, Paul B. Robbins, et al.
Cancer Immunology Research (2022) Vol. 10, Iss. 4, pp. 372-383
Open Access | Times Cited: 74
Cancer immune escape: MHC expression in primary tumours versus metastases
Federico Garrido, Natalia Aptsiauri
Immunology (2019) Vol. 158, Iss. 4, pp. 255-266
Open Access | Times Cited: 129
Beneficial autoimmunity improves cancer prognosis
Laurence Zitvogel, Claude Perreault, Olivera J. Finn, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 591-602
Open Access | Times Cited: 81
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Per Anderson, Natalia Aptsiauri, Francisco Ruiz‐Cabello, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 3, pp. 556-565
Open Access | Times Cited: 77
Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy
Eliane Klein, Ann‐Christin Hau, Anaïs Oudin, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 76
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma
Marco Fangazio, Erik Ladewig, Karen Gomez, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 22
Open Access | Times Cited: 66
Cell surface sphingomyelin: key role in cancer initiation, progression, and immune evasion
Hatem Tallima, Hassan Mohamed El-Said Azzazy, Rashika El Ridi
Lipids in Health and Disease (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 57
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Eunju Shin, Seong Ho Bak, Tae‐Ho Park, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 28
STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems
Hitesh Vasiyani, Bhumika Wadhwa
Cellular Signalling (2025), pp. 111647-111647
Closed Access | Times Cited: 1
Regulation of cGAS-STING signalling in cancer: Approach for combination therapy
Hitesh Vasiyani, Bhumika Wadhwa, Rajesh Singh
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188896-188896
Closed Access | Times Cited: 20
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
Yanbin Liu, Zhenjiang Liu, Yixiao Yang, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 7, pp. 1041-1049
Open Access | Times Cited: 19
Biomarker discovery and application—An opportunity to resolve the challenge of liver cancer diagnosis and treatment
Jingtao Chen, Chao Niu, Ning Yang, et al.
Pharmacological Research (2023) Vol. 189, pp. 106674-106674
Open Access | Times Cited: 18
Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Christine Pich-Bavastro, Laura Yerly, Jérémy Di Domizio, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 17, pp. 3498-3513
Open Access | Times Cited: 16
Mechanisms of Resistance to NK Cell Immunotherapy
Christian Sordo‐Bahamonde, Massimo Vitale, Seila Lorenzo‐Herrero, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 893-893
Open Access | Times Cited: 47
Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses
Victoria A. Brentville, Rachael L. Metheringham, Ian Daniels, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000560-e000560
Open Access | Times Cited: 47
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Michael Kuske, Maximilian Haist, T. Jung, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1710-1710
Open Access | Times Cited: 22
Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma
Yamato Ogiwara, Makoto Nakagawa, Fumihiko Nakatani, et al.
Cancer Letters (2022) Vol. 537, pp. 215690-215690
Closed Access | Times Cited: 22
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy
Florian Huber, Marion Arnaud, Brian J. Stevenson, et al.
Nature Biotechnology (2024)
Open Access | Times Cited: 5
Pharmacological induction of MHC-I expression in tumor cells revitalizes T cell anti-tumor immunity
Qian Yu, Dong Yu, Xiaobo Wang, et al.
JCI Insight (2024) Vol. 9, Iss. 17
Open Access | Times Cited: 4
FcRn-guided antigen trafficking enhances cancer vaccine efficacy
Mengyu Hong, Muziying Liu, Fang Zhu, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Page 1 - Next Page

Scroll to top